Loading...
01/10 19:55
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents several challenges: ongoing financial losses, dependency on FDA approval for revenue growth, and competitive pressures. Despite some positive developments like increased sales in North America and Europe, the decline in Asia and supply chain issues are concerning. The Q&A revealed uncertainties in regulatory timelines and management's unclear responses. The unsecured loan and share sales indicate financial strain. These factors, coupled with the lack of immediate revenue change expectation, suggest a negative sentiment, likely leading to a stock price decline in the next two weeks.
Revenue $725,000 (down from $743,000), driven primarily by increased sales in North America and Europe, offset by a decline in sales in Asia.
Gross Profit $218,000 (down from $269,000), resulting in a gross margin of 30% compared to 36% year-over-year, attributed to the low revenue base.
Total Operating Expenses $3.88 million (down from $3.92 million), indicating a slight reduction in expenses year-over-year.
Net Loss $3.59 million or $0.06 per share (compared to a net loss of $3.61 million or $0.08 per share), showing a slight improvement in loss per share.
Cash and Cash Equivalents Approximately $4.0 million as of March 31, 2025, and approximately $6.2 million as of May 27, 2025, including a $2 million unsecured bridge loan from Epoch.
Net Proceeds from Share Sales $2.65 million raised from the sales of 2,124,429 ordinary shares under its at-the-market offering facility.
ProSense System Sales: Continuous growth in ProSense system and disposable probe sales in North America.
FDA Marketing Authorization: Positive high-level meeting with the FDA regarding marketing authorization for ProSense in treating early-stage low-risk breast cancer.
Market Expansion: Potential commercial sales commencement in the US for ProSense upon FDA approval, targeting approximately 46,000 patients annually.
Revenue Performance: Revenue for Q1 2025 was $725,000, slightly down from $743,000 in Q1 2024, driven by increased sales in North America and Europe.
Gross Profit: Gross profit for Q1 2025 was $218,000, with a gross margin of 30%.
Operating Expenses: Total operating expenses for Q1 2025 were $3.88 million, a slight decrease from $3.92 million in Q1 2024.
Bridge Loan: Received a $2 million unsecured bridge loan from Epoch Partner Investments to enhance financial flexibility.
Future Catalysts: Looking ahead to potential regulatory filings and approvals in Japan and Israel.
Regulatory Risks: The FDA's decision on marketing authorization for ProSense is contingent upon the approval of a post-market study plan, which introduces uncertainty regarding the timeline and outcome of the authorization process.
Financial Risks: The company reported a net loss of $3.59 million for Q1 2025, indicating ongoing financial challenges. Revenue fluctuations are expected until FDA marketing authorization is received.
Market Competition: The company faces competitive pressures in the medical device market, particularly in the breast cancer treatment sector, which may impact sales and market share.
Supply Chain Challenges: There is a noted decline in sales in Asia, which may indicate potential supply chain or market access challenges in that region.
Economic Factors: The company’s financial performance is influenced by broader economic conditions, which may affect sales and investment in new technologies.
FDA Meeting: IceCure Medical had a positive high-level meeting with the FDA regarding the marketing authorization request for ProSense in treating early-stage low-risk breast cancer.
Post-Market Study Plan: The FDA requested a post-market study plan after marketing authorization, which IceCure has submitted for review.
Commercial Sales: Upon FDA granting marketing authorization, IceCure plans to commence commercial sales of ProSense while running the post-market study.
Reimbursement Potential: The treatment facility cost under the CPT code is $3,800, and additional reimbursements may become available based on regulatory approval.
Bridge Loan: IceCure received a $2 million unsecured bridge loan from Epoch Partner Investments to provide additional flexibility as they await FDA decisions.
Revenue Expectations: IceCure does not expect a material change in revenues before receiving the FDA marketing authorization decision.
Financial Performance: For Q1 2025, IceCure reported revenue of $725,000, with a gross margin of 30% and a net loss of $3.59 million.
Future Catalysts: IceCure anticipates potential regulatory filings and approvals in Japan and Israel as catalysts for the rest of 2025.
Unsecured Loan from Epoch: Epoch Partner Investments Limited provided a $2 million unsecured loan to IceCure Medical Ltd.
Share Sales: The company raised $2.65 million in net proceeds from the sales of 2,124,429 ordinary shares under its at-the-market offering facility.
The company's financial performance shows declining revenue, gross profit, and margins, indicating challenges in maintaining profitability. Despite the optimism around FDA approval and market potential, the lack of a concrete timeline for regulatory approvals and the unclear management responses in the Q&A create uncertainty. The ongoing net losses and limited cash position add to financial strain. These factors, combined with supply chain and sales variability, suggest a negative market reaction, likely in the -2% to -8% range, especially given the lack of market cap information for a more precise prediction.
The earnings call reveals several concerns: declining revenue and gross margin, increased net loss, and dependency on FDA approval for U.S. market growth. The Q&A highlighted uncertainties around the post-market study budget and lack of specific sales projections for Europe and Japan. While there is interest in ProSense and potential reimbursement, the financial metrics and market adoption risks overshadow these positives, suggesting a negative sentiment.
The earnings call presents several challenges: ongoing financial losses, dependency on FDA approval for revenue growth, and competitive pressures. Despite some positive developments like increased sales in North America and Europe, the decline in Asia and supply chain issues are concerning. The Q&A revealed uncertainties in regulatory timelines and management's unclear responses. The unsecured loan and share sales indicate financial strain. These factors, coupled with the lack of immediate revenue change expectation, suggest a negative sentiment, likely leading to a stock price decline in the next two weeks.
The earnings call reflects a mixed to negative sentiment. Despite some positive developments like sales growth in North America and Europe, the overall financial performance is weak with declining revenue, gross profit, and margins. The uncertainty around FDA approval and the need for a post-market study pose significant risks. Additionally, the issuance of new shares and reliance on loans indicate financial strain. The Q&A session highlights management's inability to provide clear guidance, further contributing to negative sentiment. These factors suggest a likely negative stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
